Skip to main content

View full-text article in PMC

. 2023 Jan 20;24(3):2079. doi: 10.3390/ijms24032079

Table 2.

CRP-targeting agents.

Target	Agent	Stage of Development	Main Findings
CRP translation	ISIS 280290	Animal models	No antiatherogenic effect was shown in a rabbit model of atherosclerosis.
CRP translation	ISIS 329993	Phase II clinical trials	No benefit was shown in atrial fibrillation or rheumatoid arthritis treatment.
CRP dissociation	1,6-bisPC	Animal models	Myocardial damage and renal damage were reduced in rat models of myocardial and renal IRI, respectively.
CRP dissociation	C10M	Animal models	Renal damage was reduced and allograft rejection prevented in rat models of renal IRI and hindlimb transplantation, respectively.
mCRP	mAb C3	Animal models	Joint damage and renal damage were reduced in murine models of rheumatoid arthritis and lupus nephritis, respectively.

CRP, C-reactive protein; mCRP, monomeric C-reactive protein; 1,6-bisPC, 1,6-bis(phosphocholine)-hexane; mAb, monoclonal antibody; IRI, ischemia/reperfusion injury.